FDA Requires Vision Loss Warning Label for GLP-1 Weight-Loss Drugs
The U.S. Food and Drug Administration (FDA) is mandating that GLP-1 receptor agonist drugs, including Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide), include a warning label regarding a rare risk of vision loss. This regulatory move follows concerns over potential ocular side effects associated with these popular weight-loss therapies. The requirement aims to ensure healthcare providers and patients are informed about the specific risks linked to these medications. While both Eli Lilly and Novo Nordisk dominate the obesity treatment market, this labeling update introduces new safety considerations for their flagship products.
Topics: drug labeling FDA regulation GLP-1 agonists weight loss drugs
Read the full article at Seeking Alpha
Part of the story Novo Nordisk reports liver improvements with Wegovy in some patients (2 articles)